key: cord-0901924-0wibkuwm authors: Monpara, Jasmin D.; Sodha, Srushti J.; Gupta, Pardeep K. title: COVID-19 associated complications and potential therapeutic targets. date: 2020-09-12 journal: Eur J Pharmacol DOI: 10.1016/j.ejphar.2020.173548 sha: d1e356766e04b7708089e8e95099cf0d7a243e41 doc_id: 901924 cord_uid: 0wibkuwm The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19. to clinical improvement and mortality at 28 days (Cao et al., 2020a) . Improvement in the 281 course of COVID-19 was studied in a prospective, phase 2 clinical trial. Patients were 282 randomized in two groups, a combination of lopinavir and ritonavir (400mg -100 mg 283 respectively) alone versus lopinavir + ritonavir (same dose) in combination with interferon 284 beta-1b (3 doses of 8 million international units). The combination group had a significantly 285 shorter median time from start of study treatment to negative nasopharyngeal swab (7 days) 286 than the control group (12 days). Although, only the combination of lopinavir-ritonavir with 287 interferon significantly reduced the time to negative nasopharyngeal swab, it was seen that 288 both the treatments were safe and efficacious (Hung et al., 2020) . Lopinavir/ritonavir 289 treatment arm was included in WHO's Solidarity Trial. However, in addition to 290 pg. 14 hydroxychloroquine arm, the lopinavir/ritonavir arm was discontinued on July 04, 2020 due 291 to little or no reduction in the mortality of hospitalized COVID-19 patients when compared to 292 standard of care in the interim trial results. The WHO stated that "This decision applies only 293 to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible 294 evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized 295 patients or as pre-or post-exposure prophylaxis for COVID-19." (World Health 296 Organization, 2020). 297 Anthelmintic drugs such as ivermectin and levamisole have potential immunomodulatory and 299 antiviral properties. The exact mechanism of virus inhibition is not reported yet, but it is 300 speculated that inhibition of importin α/β1 mediated transport of viral proteins in and out of 301 the nucleus may be responsible for the antiviral activity (Gupta et al., 2020 that the dose-response gains could be attributed to the shielding of SARS-CoV-2 spike 321 proteins by ivermectin. It is believed that in addition to ACE-2 receptors, SARS-CoV-2 also 322 bind to the CD147 transmembrane receptor via spike proteins. The CD147 are found 323 abundantly on the red blood cells (RBCs) and SARS-CoV-2 is hypothesized to cause 324 clumping of RBCs impending the blood flow. The author also hypothesized that ivermectin 325 could prevent the RBC clustering by shielding the spike proteins (Scheim, 2020). These 326 studies are still at initial stage of investigation and more evidence are needed to establish the 327 efficacy of ivermectin in COVID-19. The Anthelmintic drugs currently investigated in the 328 clinical trials are listed in Table 2 . (Table 3) . Table 5 . Table 7. pg. 29 Although new knowledge pertaining to COVID-19 is emerging every day, it has become 627 clear that COVID-19 is complex disease involving interactions of respiratory system, 628 cardiovascular system, and other major organs. The hyper inflammation and 629 hypercoagulation associated with COVID-19 are major contributing factors toward the 630 disease severity and mortality. Extensive research is being carried out by the research 631 institutes and pharmaceutical industries evident from the number of ongoing clinical trials. 632 As we await more data on the efficacy of ongoing clinical studies, hope remains that we 633 overcome this pandemic and based on the lessons learned in COVID-19 pandemic, we 634 prepare ourselves to prevent any future pandemic. 635 Authors declare no conflict of interest. 637 All authors contributed equally to the preparation of the manuscript. Experimental 677 Treatment with Favipiravir for COVID-19: An Open-Label Control Study The FDA-approved 680 drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Covid-19 -Navigating the Uncharted Observational 738 Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure Coagulation disorders in coronavirus infected 749 patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past Ivermectin: potential candidate for the treatment of Covid 19 The human-COVID-19 Tango: Connecting the Dots SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 772 Blocked by a Clinically Proven Protease Inhibitor Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for Alpha-1 adrenergic receptor 978 antagonists for preventing acute respiratory distress syndrome and death from cytokine 979 storm syndrome Vasoactive intestinal 981 polypeptide/phentolamine for intracavernosal injection in erectile dysfunction SARS 984 coronavirus entry into host cells through a novel clathrin-and caveolae-independent 985 endocytic pathway Remdesivir and chloroquine effectively inhibit the recently emerged novel 988 coronavirus (2019-nCoV) in vitro Early, low-dose and short-term application of corticosteroid treatment in patients with 992 severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv WHO discontinues hydroxychloroquine and 1012 lopinavir/ritonavir treatment arms for COVID-19 Association Between Hypoxemia and Mortality in Patients With COVID-19 Proc Effective treatment of severe COVID-19 patients with 1020 tocilizumab Targeting the Endocytic Pathway and Autophagy Process as a 1023 Novel Therapeutic Strategy in COVID-19 Song, pathogens Clinical course and risk factors for mortality of adult inpatients with COVID-19 in China: a retrospective cohort study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in China: a retrospective cohort study Arbidol 1052 monotherapy is superior to lopinavir/ritonavir in treating COVID-19 Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of 1056